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Abstract
Background—Electrical conduction from the cardiac sinoatrial node to the ventricles is critical 
for normal heart function. Genome-wide association studies (GWAS) have identified more than a 
dozen common genetic loci that are associated with PR interval. However, it is unclear whether 
rare and low-frequency variants also contribute to PR interval heritability.
Methods and Results—We performed large-scale meta-analysis of the PR interval that 
included 83,367 participants of European ancestry and 9,436 of African ancestry. The Illumina 
HumanExome BeadChip examined both common and rare variants. We identified 31 genetic loci 
that were significantly associated with PR interval after Bonferroni correction (P<1.2×10−6), 
including 11 novel loci that have not been reported previously. Many of these loci are involved in 
heart morphogenesis. In gene-based analysis, we found that multiple rare variants at MYH6 (P = 
5.9×10−11) and SCN5A (P=1.1×10−7) were associated with PR interval. SCN5A locus also was 
implicated in the common variant analysis, whereas MYH6 was a novel locus.
Conclusion—We identified common variants at 11 novel loci and rare variants within two gene 
regions that were significantly associated with PR interval. Our findings provide novel insights to 
the current understanding of atrioventricular conduction, which is critical for cardiac activity and 
an important determinant of health.
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Introduction
Electrical conduction from the cardiac sinoatrial node to the ventricles is critical for normal 
heart function. Abnormalities of atrioventricular conduction can cause significant morbidity, 
and have been associated with atrial fibrillation (AF),1,2 need for pacemaker implantation,2 
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cardiac malformations, and sudden death.3,4 Conduction from the sinus node through the 
atria, atrioventricular node, and His-Purkinje fibers is readily evaluated from surface 
electrocardiogram (ECG), by measurement of the duration of PR interval. Despite the 
critical role that the cardiac conduction system plays in cardiac physiology and disease, the 
formation and regulation of the conduction system remains incompletely understood.
Recent data indicate that cardiac conduction measurements are heritable5–7 and have a 
genetic basis.8–11 To date, genetic studies of PR interval have been relatively modest-sized 
largely European-ancestry samples, and have implicated cardiac expressed ion channels, 
cardiac developmental transcription factors, signaling molecules, as well as novel pathways 
not previously known to be involved in cardiac conduction processes. Nevertheless, existing 
studies have focused on the role of common and predominantly noncoding genetic variants, 
which account for only a modest proportion of trait heritability.6
To better understand the biological and potential clinical implications of genetic variation 
underlying cardiac conduction, there is a need to examine both common and rare variation 
underlying atrioventricular conduction in large, well-powered, multiethnic studies. 
Moreover, assessment of genetic variation that alters protein coding has the potential to more 
directly implicate genes involved in processes critical to cardiac conduction. We therefore 
sought to examine PR interval duration in relation to predominantly coding genetic variants, 
in large, multi-ethnic analyses using the exome chip.
Methods
The data, analytic methods, and study materials will be made available to other researchers 
for purposes of reproducing the results, subject to Data Use/Sharing Agreements adopted by 
individual participating cohorts. The summary results from the current manuscript are 
available at the Broad Cardiovascular Disease Knowledge Portal (www.broadcvdi.org).
Study participants
The current project included participants of European ancestry (EA) from 22 studies: Age, 
Gene/Environment Susceptibility Study (AGES); Atherosclerosis Risk in Communities 
study (ARIC); British Genetics of Hypertension (BRIGHT); Massachusetts General Hospital 
Cardiology and Metabolic Patient cohort (CAMP); Cardiovascular Health Study (CHS); 
Erasmus Rucphen Family Study (ERF); Framingham Heart Study (FHS); Genes for 
Cerebral Hemorrhage on Anticoagulation (GOCHA); Genetic Regulation of Arterial 
Pressure In Humans in the Community (GRAPHIC); INTER99; Cooperative Health 
Research in the Region Augsburg (KORA); CROATIA-Korcula (KORCULA); LifeLines 
Cohort Study (LifeLines); Multi-Ethnic Study of Atherosclerosis (MESA); The Netherlands 
Epidemiology of Obesity (NEO); Rotterdam Study (RS); Generation Scotland: Scottish 
Family Health Study (GS:SFHS); Study of Health in Pomerania (SHIP); TwinsUK; Utrecht 
Health Project (UHP); Women’s Health Initiative (WHI); and Young Finns Study (YFS).
In addition, we included participants of African ancestry (AA) from five studies. These 
studies included ARIC, CHS, Jackson Heart Study (JHS), MESA and WHI.
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Institutional Review Boards or Ethics Committees approved study procedures at each 
contributing site. All participants provided written informed consent to participate in genetic 
research.
Measurement of PR interval
PR interval duration, in milliseconds, was measured from the onset of the P wave to the 
onset of the QRS interval for each cohort. The following exclusions were applied: extreme 
PR values (≤ 80 ms or ≥ 320 ms); second or third degree heart block; atrial fibrillation on 
baseline ECG; history of myocardial infarction, heart failure, or Wolff–Parkinson–White 
syndrome; pacemaker placement; use of class I or III blocking medications (ATC code 
prefix C01B); digoxin use (ATC code C01AA05) or pregnancy.
Genotyping
Genotyping was performed independently in each study using the Illumina Human Exome 
BeadChip (v1.0, 1.1, or 1.2). Data were called and cleaned according to CHARGE 
ExomeChip best practices.12 Detailed information for each study regarding genotyping 
platforms, variant calling, and quality control metrics is shown in Supplementary Table 1. 
All studies used the same set of reference alleles to recode variants to ensure consistency.
Statistical analyses
Prior to association analysis, PR interval was first adjusted for covariates by taking residuals 
from a linear regression of PR on age, sex, height, body mass index, and RR interval. Each 
cohort additionally adjusted as necessary for cohort-specific variables, such as clinic sites, 
family structure, and population structure. To reduce sensitivity to extreme PR values, the 
residuals were inverse-normal transformed and used as the outcome for association testing.
Because single-marker based analyses typically have low power to identify associations 
between rare variants and traits, we separated the analysis for common and rare variants 
based on minor allele frequency (MAF). Common variants were defined as those with 
MAF≥1%, and the remaining variants were defined as rare variants (MAF<1%). For each of 
the common variants, we evaluated its association with the transformed PR interval, and 
accounted for multiple testing by Bonferroni correction (P < 0.05/42075=1.2×10−6). For the 
rare variants, we restricted analyses to nonsynonymous or splicing variants with MAF <1%, 
because such variants are more likely to be functional than synonymous or more common 
variants. As we expect some rare variants may act in the same or opposite directions even in 
the same gene region,13 we used a modified version of the Sequence Kernel Association Test 
(SKAT),14 which avoids problems of signals cancelling out each other in burden test results. 
Many gene regions had few or no rare nonsynonymous or splicing variants. Monomorphic 
variants from each study also were reported in the cohort level results as they were used for 
the cumulative MAF computations in gene-based tests. Gene regions with a cumulative 
MAF of rare variants <1% were excluded, resulting in 5,761 gene regions that were tested 
(see results below). Therefore, Bonferroni-corrected significance threshold for our gene-
based tests was P<0.05/5,761=8.7×10−6. In secondary analyses, we limited the analysis to 
damaging variants, defined as nonsense variants or variants predicted to be damaging by 
PolyPhen-215 or SIFT.16
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Analyses were performed using the “prepScores” function of the “seqMeta” R package. 
Family-based studies implemented the “kins” option in “prepScores” to specify kinship 
matrices. Each study provided single variant z-statistics from score tests, as well as genotype 
covariance matrices, which were then combined by fixed effects meta-analysis. The 
heterogeneity across studies was assessed by the Cochran’s Q, which is a non-parametric 
statistical test defined as the weighted sum of squared differences between individual study 
effects and the pooled effect. We performed both race stratified and race combined meta-
analyses, and the race combined results were used for the remaining sections unless stated 
otherwise.
Comparison with genetic loci associated with AF and P-wave indices (PWI)
We also compared genetic loci associated with PR interval with those associated with AF 
and PWI to see if there are any shared genetic mechanisms. “AF loci” were identified by a 
recent exome chip analysis that included 22,806 AF cases and 132,612 referents.17 “PWI 
loci” were identified from a meta-analysis of P-wave duration and P-wave terminal force 
that included 44,456 participants.18 In addition, for each of the top variants associated with 
PR, we also examined its association with AF and PWI.
Examine potential function of PR-related variants for gene expression, regulation and 
biological pathways
Pathway analysis was performed by MAGENTA19 with default settings. The summary result 
for the common variants was used as the input, and significant pathways were defined as 
those with a false discovery rate (FDR)20 <0.05. The implication of genetic variants on 
cardiac gene expression (eQTL analysis) was performed by querying the GTEx database.21 
At each PR-related locus, we identified the top variant and its neighboring variants that were 
within 500kb and in linkage disequilibrium with the top variant (r2 ≥ 0.5). Four heart and 
vascular tissues were queried, including artery aorta, artery coronary, atrial appendage and 
heart left ventricle. Significant eQTLs were defined as those with FDR<0.05. Regulatory 
regions were downloaded from the ENCODE Project22 and the NIH Roadmap Epigenomics 
Program.23 Four tracks were created: 1) included all 98 cell types from Roadmap 
epigenomics H3K27ac sites; 2) included only four heart tissues (aorta, right atrium, left 
ventricle, right ventricle) from Roadmap epigenomics H3K27ac sites; 3) included all 125 
cell lines from ENCODE DNaseHS sites; 4) included only three heart-derived cell lines 
(cardiac fibroblasts, atrial fibroblasts, cardiac myocytes). The enrichment of PR-related loci 
in regulatory regions was examined by the “VSE” R package.24 For comparison, we 
randomly created 1,000 variant sets with MAF values and LD structures similar to those 
seen for PR-related loci.
Results
The current analyses included a total of 92,803 individuals from 27 cohorts, with 83,367 
individuals from 22 studies of European ancestry and 9,436 individuals from 5 studies of 
African ancestry. Clinical characteristics of the study participants are in Table 1.
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Identification of 31 loci associated with PR interval
A total of 42,075 common variants were analyzed (MAF ≥ 1%). As shown in Figure 1 and 
Table 2, 31 loci were significantly associated with PR interval after Bonferroni correction (P 
< 1.2×10−6), including 22 loci that reached the conventional genome-wide significance 
threshold (P < 5×10−8). The results of the random effects meta-analysis were similar to those 
of the fixed effects analysis (Supplementary Table 2). The most significant locus was tagged 
by rs6795970 (P= 4.0×10−240), a missense variant in SCN10A, which encodes a sodium 
channel that has been associated previously with the PR interval (r2=0.97 with the top SNP 
rs6599250 reported previously).8 Highly associated variants clustered in the linker region 
between the second and third domains of SCN10A (Figure 2). The top variants at 12 loci are 
missense variants. In addition, the top variants at 4 loci (including 3 novel loci) are low-
frequency variants (1% < MAF < 5%), illustrating the power of exome chip analyses to 
identify low-frequency coding associations. Detailed information of the nearest gene to each 
genome wide significant locus is given in Supplementary Table 3.
We then examined the associations between these top PR variants with AF and 
electrocardiographic PWI. Eight out of 31 PR loci identified in our analysis were associated 
with AF after Bonferroni correction (P<0.05/31=1.6×10−3), consistent with some shared 
mechanisms between the regulation of PR interval and AF. Variants in SCN10A most 
significantly associated with PR interval were also significantly associated with AF 
(Supplementary Table 4). Among PR-related SNPs, rs60632610 at the SYNPO2L locus was 
most significantly associated with AF (Odds ratio: 1.90 (0.87-0.93), P=1.5×10−10). 
Supplementary Figure 1 shows the overlap among loci associated with PR interval, AF, and 
PWI.
We also performed a sensitivity analysis that separated samples of European and African 
ancestry. As shown in Supplementary Table 5 and Supplementary Figure 2, all of the 31 loci 
except rs17391905 at the 1p32.3 locus (P = 2.6×10−6) were also significant in the analysis of 
European-only samples. Supplementary Table 6 and Supplementary Figure 3 show the result 
for the analysis of African ancestry-only samples. Three loci were significant: SCN5A 
(rs3922844), SCN10A (rs6795970), and TBX5 (rs883079) after Bonferroni correction; P < 
1.3 × 10−6. All three loci were also significant in the analysis of European-only samples. 
The result from each individual study is shown in Supplementary Table 7.
Rare variations in MYH6 and SCN5A are associated with PR interval
We next examined the association between PR interval and rare variants (MAF<1%) in gene 
regions. Variation in two gene regions, MYH6 (P = 5.9×10−11) and SCN5A (P = 1.1×10−7), 
was associated with PR interval (Table 3). Supplementary Tables 8 and 9 show the 
association of each rare variant within MYH6 and SCN5A with PR interval, respectively. 
MYH6 encodes a cardiac myosin heavy chain subunit, and SCN5A encodes the major 
cardiac sodium channel and was previously found to be associated with PR interval.8 MYH6 
was also recently found to associate with PWI.18 We also performed an ancestry-stratified 
analysis in the same way as the combined analysis. The same two gene regions were 
significant using data from European samples alone (P = 4.1×10−12 and 8.3×10−7 for MYH6 
and SCN5A, respectively). These two genes did not reach the significance cutoff in African 
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samples (P = 0.03 and 0.01 for MYH6 and SCN5A, respectively). Two other genes, 
HEATR2 (P = 2.2×10−−6) and THRAP3 (P = 4.2×10−6), were significantly associated in 
African samples alone. However, in the combined analysis, these two genes were not 
significant (P=0.02 and 0.06 for HEATR2 and THRAP3, respectively), probably due to a 
low cumulative allele frequency.
In our secondary analysis of pooled samples, we analyzed only damaging variants, defined 
as nonsense mutations or alternations predicted to be damaging by PolyPhen-215 or SIFT.16 
Three genes reached the signifiance cutoff (P<0.05/2030=2.5×10−5), including GORASP1 
(P=1.1×10−5), NEBL (P=1.9×10−5), and SCN5A (P=2.2×10−5) (Supplementary Table 10).
Expression quantitative trait loci (eQTL) analysis
We also performed eQTL analysis to determine if any of the novel PR-related variants were 
associated with cardiac gene expression using data from GTEx.21 Eight loci were associated 
with expression of at least one gene in the atrial appendage, left ventricle, coronary artery, or 
aorta, suggesting the importance of these loci in the regulation of gene expression in heart or 
vascular tissues (Supplementary Table 11).
Enrichment of PR-related variants in regulatory regions
We examined involvement of PR-related variants in regulatory function. As shown in 
Supplementary Figure 4, PR-related variants were significantly enriched in regulatory 
regions in both primary heart tissues (Padj=3.7×10−9) and heart-derived cell lines 
(Padj=0.002), but not in all tissues (Padj>0.05). The observed enrichment suggested 
involvement of these loci in tissue-specific regulatory functions. In addition, the variants also 
tended to locate within evolutionarily conserved regions (Padj=2.8×10−5 for primates and 
6.4×10−5 for mammals).
Enrichment of PR-related variants in biological pathways
We examined the enrichment of PR-related variants in biological pathways by MAGENTA.
19
 Supplementary Table 12 shows the top pathways identified. The most significant pathway 
was heart morphogenesis (P=3.6×10−5, FDR=0.049), suggesting that many PR-related genes 
might be involved in cardiac development. The pathway was only the significant pathway 
after correction for multiple testing (FDR<0.05).
Discussion
We conducted a large-scale analysis of the genetic determinants of atrioventricular 
conduction in 92 803 individuals by studying the electrocardiographic PR interval. In total, 
we observed 31 genetic loci that were associated with atrioventricular conduction, 11 of 
which are novel. In aggregate, the results implicate loci containing genes encoding ion 
channels in the heart, sarcomeric proteins, cardiac transcription factors, and other proteins 
with unknown cardiac function. Our findings provide new insights to the current 
understanding of atrioventricular conduction, which is critical for cardiac function.
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Interestingly, rare variants in SCN5A and MYH6 were associated with PR interval. A 
missense mutation (D1275N) in SCN5A has previously been reported in a large family with 
multiple members affected by dilated cardiomyopathy, conduction disorder, and arrhythmia.
25
 The mutation, together several other mutations within the same gene, has also been 
associated with dilated cardiomyopathy,26 atrial fibrillation,27 and long-QT syndrome.28–31 
Rare mutations within MYH6 were associated with sick sinus syndrome,28 congenital heart 
defects,32 and atrial septal defects.33
Our observations support and extend prior analyses of cardiac conduction. Most previous 
genome-wide association studies involved the study of common genetic variation in smaller 
samples of up to 28,517 individuals.8,10,11 In keeping with those prior studies, we again 
observed that SCN10A is the most prominent gene involved in atrioventricular conduction. 
Our recent GWAS based on 105K samples corroborates many of our current findings.34 
However, our current study had greater power than those earlier analyses for assessment of 
rare coding variation.
Our study has two major implications. First, our results underscore the utility of assessing 
coding variation as an efficient way to identify functional molecular domains. In particular, 
our findings provide insights into the functional topology of SCN10A. The SCN10A sodium 
channel gene is widely expressed in the nervous system and heart,21 but it has only recently 
been implicated in cardiac conduction8,34–36 and arrhythmias such as AF35 and Brugada 
syndrome.37 SCN10A encodes an alpha subunit (with six transmembrane spanning regions), 
which forms tetrameric, voltage gated sodium channels responsible for the Nav 1.8 late 
sodium channel current.38,39 We found a collection of amino acid substitutions in the linker 
region between the second and third domains of SCN10A that were associated with PR 
duration (Figure 2). Variants in this linker region that were associated with the PR interval 
also were associated with AF, suggesting that function of this domain may have important 
clinical implications.
Prior work on the homologous SCN5A cardiac sodium channel gene – which is also a 
cardiac conduction locus – indicates that this linker region is critical for sodium channel 
inactivation. Sodium influx is predominantly responsible for cardiomyocyte depolarization. 
Moreover, channel inactivation is essential for restoration of the hyperpolarized state needed 
for cyclic cardiomyocyte depolarization and contraction. Therefore, variations in this linker 
region might be involved in Nav 1.8 inactivation. Other data are necessary to identify 
relationships among variation in the linker region, the late sodium channel current, and 
channel inactivation in both healthy and diseased states.
Together with previously discovered susceptibility genes, our findings implicate genes in 
different functional classes that regulate atrioventricular conduction such as ion channels and 
cardiac transcription factors. In many cases, anomalies in these genes have been found to 
cause human cardiac diseases, such as congenital heart defects, primary cardiac conduction 
abnormalities, and syndromes predisposing to sudden cardiac death (Supplementary Table 
3). Interestingly, some of the genes are not expressed (in high abundance) in the right atrial 
appendage or the left ventricle, according to existing data sets – although most are active in 
the heart (Supplementary Table 13). Atrioventricular nodal conduction also can be 
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influenced by external tone from the autonomic nervous system. Therefore, further work is 
necessary to determine the mechanisms by which identified genes that are not expressed in 
the heart influence the PR interval.
We acknowledge several limitations of our study. Because PR interval was measured across 
many cohorts, it is possible that there is some heterogeneity that would diminish our power 
to detect modest associations. We excluded individuals with extreme values of PR interval, 
which might have been gleaned from large variations in cardiac conduction. We also 
performed inverse normal transformation on the raw PR interval to reduce the heterogeneity, 
which on the other hand might reduce the interpretability. Although we performed single-
variant and gene-based tests, we did not examine the association of haplotype patterns with 
PR interval, so it is unclear if there are any haplotypes that might be associated with PR 
interval. Most of the genetic variants analyzed were in exons. Therefore the effects of 
variants within regulatory regions were not investigated. We note that the variants identified 
may not be causally related to the studied phenotypes (PR interval, AF, and PWI), but may 
be in LD with causal variants. We anticipate that future increases in sample size with 
additional replications and more comprehensive genotyping platforms, such as denser SNP 
arrays or genome sequencing, will help address these limitations.
In conclusion, we studied genetic variants associated with PR interval duration and 
identified 31 common loci – including 11 that were novel – and two rare variant regions. Our 
findings greatly expand our knowledge of the genes that underlie atrioventricular conduction 
in the heart.
Supplementary Material
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Clinical Perspective
The duration of PR interval is an important biomarker of the cardiac conduction system. 
Increasing evidences suggest that cardiac conduction measurements including PR interval 
are heritable. It is thus interesting to understand the biological and potential clinical 
implications of genetic variation underlying cardiac conduction. We performed a large-
scale meta-analysis of PR interval that included 83,367 participants of European ancestry 
and 9,436 of African ancestry using the Illumina exome chip. Thirty-one genetic loci 
were significantly associated with PR interval after Bonferroni correction, including 11 
loci that have not been previously reported. Our findings provide new insights to the 
current understanding of atrioventricular conduction, which is critical for cardiac activity 
and an important determinant of health.
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Figure 1. Manhattan plot showing the association between common variants and PR interval 
from combined ancestry analysis
The x-axis represents the chromosomal position for each SNP, and the y-axis represents the 
–log10(p-value) of the association with PR interval. The dashed line represents the genome-
wide significance cutoff of 5×10−8, and the blue line represents the Bonferroni P-value 
cutoff of 1.3×10−6. Black color represents known loci, whereas red color represents novel 
loci.
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Figure 2. Diagram of sodium voltage-gated channel alpha subunit 10 (SCN10A)
Each yellow circle represents a genetic variant with a P-value less than the significance 
cutoff (1.2 × 10−6). Each red circle represents a genetic variant with a P-value greater than 
the significance cutoff, but less than 0.05.
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